$インネート・ファーマ(IPHA.US)$ NEWS Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the first patient was dosed in the Phase 2 dose expansion part of the Sanofi-sponsored clinical trial of SAR443579 / IPH6101 (NCT05086315), evaluating SAR443579 as a monothe...
$インネート・ファーマ(IPHA.US)$ NEWS Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate Innate Pharma SA announces promising preclinical data for IPH45, a novel exatecan-Antibody Drug Conjugate targeting Nectin-4, showing stronger activity than EV in urothelial tumors. IPH45 demonstrates anti-tumor efficacy in various solid tumors and EV-refractory models, with plans for IND in 2024. 🔸Promising preclinical data for IPH4...
$インネート・ファーマ(IPHA.US)$Innate Pharma (NASDAQ:IPHA) reported quarterly losses of $(0.10) per share. This is a 87.2 percent increase over losses of $(0.75) per share from the same period last year. The company reported $66.35 million in sales this quarter. This is a 12.71 percent increase over sales of $58.87 million the same period last year.
$インネート・ファーマ(IPHA.US)$I think i may call that 3 stars in the south on the daily? Hmm News, and a common reversal pattern! Yes watching very close for a bit of a pullback and volume? And i just may have to try this if i get confirmation? With SL tight! Just thinking outloud! hehehe
1
2
報告
Moo Top :
I guess will probable run a while... keeping it for 3.5 out
$インネート・ファーマ(IPHA.US)$Sanofi Exercises Option to License 4th NK Cell Engager Program in Solid Tumors From Innate Pharma's ANKET Platform Sanofi (SNY) has exercised its option to license its fourth natural killer cell engager program in solid tumors from Innate Pharma's (IPHA) Antibody-based NK Cell Engager Therapeutics, or ANKET, platform, according to a Tuesday statement. The ANKET is Innate's platform for developing multi-specific natural killer...
インネート・ファーマに関するコメント
NEWS
Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the first patient was dosed in the Phase 2 dose expansion part of the Sanofi-sponsored clinical trial of SAR443579 / IPH6101 (NCT05086315), evaluating SAR443579 as a monothe...
NEWS
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
Innate Pharma SA announces promising preclinical data for IPH45, a novel exatecan-Antibody Drug Conjugate targeting Nectin-4, showing stronger activity than EV in urothelial tumors. IPH45 demonstrates anti-tumor efficacy in various solid tumors and EV-refractory models, with plans for IND in 2024.
🔸Promising preclinical data for IPH4...
NEWS
Innate Pharma SA (Nasdaq: IPHA) executives to attend Van Lanschot Kempen conference in Amsterdam on April 16-17, 2024.
Not bad
Ph2 readouts in Q1 2024...
$リープ・セラピューティクス(LPTX.US)$ Phase 2
$ヴェラ・セラピューティクス(VERA.US)$ Phase 2b
$4Dモレキュラー・セラピューティクス(FDMT.US)$ Phase 2
$アドベラム・バイオテクノロジーズ(ADVM.US)$ Phase 2
$デナリ・セラピューティクス(DNLI.US)$ Phase 2
$アケロ・セラピューティクス(AKRO.US)$ Phase 2b
$スプルース・バイオサイエンシズ(SPRB.US)$ Phase 2
$ゼンコー(XNCR.US)$ Phase 2
$アルナイラム・ファーマシューティカルズ(ALNY.US)$ Phase 2
$ハーモニー・バイオサイエンシーズ(HRMY.US)$ Phase 2
$アネクソン(ANNX.US)$ Phase 2a
$ロイバント・サイエンシズ(ROIV.US)$...
Upcoming Ph 2 readouts in Q1 2024…
$リジェネックスバイオ(RGNX.US)$ Phase 2
$リープ・セラピューティクス(LPTX.US)$ Phase 2
$4Dモレキュラー・セラピューティクス(FDMT.US)$ Phase 2
$アドベラム・バイオテクノロジーズ(ADVM.US)$ Phase 2
$デナリ・セラピューティクス(DNLI.US)$ Phase 2
$アイポイント・ファーマシューティカルズ(EYPT.US)$ Phase 2
$ゼンコー(XNCR.US)$ Phase 2
$ハーモニー・バイオサイエンシーズ(HRMY.US)$ Phase 2
$アルナイラム・ファーマシューティカルズ(ALNY.US)$ Phase 2
$ディスク・メディシン(IRON.US)$ Phase 2
$アテア・ファーマシューティカルズ(AVIR.US)$ Phase 2
$アラコス(ALLK.US)$ Phase 2...
Offering
Hehehe!
Reversal pattern on the daily?
With this news it could get interesting today?
Sanofi (SNY) has exercised its option to license its fourth natural killer cell engager program in solid tumors from Innate Pharma's (IPHA) Antibody-based NK Cell Engager Therapeutics, or ANKET, platform, according to a Tuesday statement.
The ANKET is Innate's platform for developing multi-specific natural killer...
まだコメントはありません